ARCT
Arcturus Therapeutics Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.42
+0.77%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$10.47
From 52W high−55.01%
Volume635658.00
Market cap$296.17M
P/E (TTM)—
P/S (TTM)12.4x
Div yield—
Key dataOct 19, 2026
Open
$10.47
From 52W high
−55.01%
Volume
635658.00
Market cap
$296.17M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
P/E (TTM)
—
RSI (14)
36.2
MomentumView details →
1D Return
+0.77%
YTD Return
+69.90%
SummaryUpdated Jun 1, 2026
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a biotechnology company founded in 2013 and headquartered in San Diego, California. The company specializes in developing RNA-based medicines, focusing on vaccines for infectious diseases and therapeutic treatments for rare genetic disorders affecting the liver and respiratory system. Since going public in 2013, Arcturus has evolved from an early-stage biotech into a clinical-stage company with multiple programs in human trials and its first approved product - a COVID-19 vaccine launched in Japan.
Similar companies
Latest newsMore news →
Arcturus Therapeutics announced encouraging interim Phase 2 results for ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced its next-generation mRNA delivery platform LUNAR 2.0 along with additional liver pipeline programs.26d agoArcturus Therapeutics announced it will host a virtual presentation on September 23, 2026, to provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and its mRNA liver therapeutics platform.31d agoArcturus Therapeutics reported a second-quarter loss of $0.84 per share, beating the Zacks Consensus Estimate of a loss of $1.07, and compared to a loss of $0.34 per share a year ago.74d ago